The Use Of A Multidrug Pill In Reducing Cardiovascular Events (UMPIRE) Trial
Funder
National Health and Medical Research Council
Funding Amount
$314,535.00
Summary
Patients who have cardiovascular disease are at very high risk of experiencing a heart attack or stroke, and current guidelines recommend the long-term use of aspirin, blood pressure lowering drugs and a cholesterol lowering drug in such patients to reduce their risks. The proposed research will investigate whether the availability of a polypill (a single pill containing all these drugs) will help ensure patients are appropriately prescribed these treatments, and keep taking them long-term. Aust ....Patients who have cardiovascular disease are at very high risk of experiencing a heart attack or stroke, and current guidelines recommend the long-term use of aspirin, blood pressure lowering drugs and a cholesterol lowering drug in such patients to reduce their risks. The proposed research will investigate whether the availability of a polypill (a single pill containing all these drugs) will help ensure patients are appropriately prescribed these treatments, and keep taking them long-term. Australian researchers will have a pivotal role in collecting and interpreting the data in this trial. In addition, Australian researchers will combine the findings of this study with results from similar trials being conducted in Australia (1600 patients, including 600 Aboriginal participants) and New Zealand (600 patients, including 600 Maori participants). This overview will provide very accurate information about the usefulness of the polypill, and how it should be used worldwide.Read moreRead less
Care-seeking, Use Of CAM, And Self-management Among People With Type 2 Diabetes And
Funder
National Health and Medical Research Council
Funding Amount
$663,576.00
Summary
Chronic disease and related health problems are increasing in prevalence in Australia. Recent estimates suggest that Type 2 diabetes and heart disease cost the Australian community almost $9 billion in direct costs per annum. People with chronic conditions follow medical and behavioural prescriptions variably, however, while also using complementary and alternative (CAM) therapies, practitioners, vitamins and herbs. We will explore the reasons for presentation to and use of CAM practitioners and ....Chronic disease and related health problems are increasing in prevalence in Australia. Recent estimates suggest that Type 2 diabetes and heart disease cost the Australian community almost $9 billion in direct costs per annum. People with chronic conditions follow medical and behavioural prescriptions variably, however, while also using complementary and alternative (CAM) therapies, practitioners, vitamins and herbs. We will explore the reasons for presentation to and use of CAM practitioners and therapies by people diagnosed with and under treatment for two of the most commonly diagnosed chronic conditions - cardiovascular disease and diabetes - in order to establish the relationship with adherence to their prescribed treatment. The focus is on what is described as the “drivers, costs and benefits” of the use of CAM, and how the practical interaction of CAM and conventional health care approaches may support adherence. This research program will have very important implications for the control of these diseases and individual wellbeing. Using an innovative interdisciplinary approach and a mix of research methods, the research will provide a unique evidencebase on community approaches to and use of complementary and alternative medicine, and the significance of this to current and future health needs. The program will take advantage of the interdisciplinary skills in novel ways to explore areas of health and society that have so far received limited attention. By including two PhDs, we will strengthen Australia’s research capacity in health social sciences and public health in this field, generating new skills important to population health practice and policy in this country.Read moreRead less
A National Resource For Mouse Models Of Mesothelioma
Funder
National Health and Medical Research Council
Funding Amount
$483,643.00
Summary
Mouse models of mesothelioma have led to a greater understanding of the disease and the identification of potential drug therapies some of these have now been translated into clinical trials. In the existing models, mesothelioma cells that have been grown in the laboratory are transplanted into animals by injecting the cells under the skin. Different cell lines with different properties are used in different experimental protocols. This application will fund the establishment of a central resour ....Mouse models of mesothelioma have led to a greater understanding of the disease and the identification of potential drug therapies some of these have now been translated into clinical trials. In the existing models, mesothelioma cells that have been grown in the laboratory are transplanted into animals by injecting the cells under the skin. Different cell lines with different properties are used in different experimental protocols. This application will fund the establishment of a central resource to maintain and distribute these cell lines. In addition, we describe a new transgenic mouse model in which mesotheliomas are rapidly induced in the peritoneal cavity after exposure to asbestos, recreating the natural tumour development much more accurately. These mice have been engineered to express the cancer causing protein of a monkey virus (SV40 large T antigen) in their mesothelial cells because it has been suggested that the virus has a role in the development of mesothelioma. This application also seeks funding to use the MexTAg mice to test the usefulness of different therapies for the prevention or treatment of mesothelioma. These animals give us the ability to investigate the disease in a more realistic environment than previous models. In parallel collaborative studies with other groups investigating different aspects of the biology of this cancer, we plan to analyze the earliest changes in the development of the disease and search for early markers using proteomics and gene expression studies. We anticipate that this model will generate information more directly relevant to understanding the human disease and will provide essential experimental data for clinical trials.Read moreRead less
Screening Agents Active Against The Late-stage Inflammatory Cytokines For Activity Against Influenza Disease
Funder
National Health and Medical Research Council
Funding Amount
$241,409.00
Summary
Infection with a virulent influenza virus that the body has never encountered before, particularly H5N1, sends the immune system into overdrive, and causes a massive release of proteins (inflammatory cytokines), known as a cytokine storm, that in and of itself leads to death. The object of this research is to screen, in a mouse influenza model, agents known to prevent this occurring and antagonise it once it has occurred. This will be done with and without Tamiflu, a standard anti-influenza drug ....Infection with a virulent influenza virus that the body has never encountered before, particularly H5N1, sends the immune system into overdrive, and causes a massive release of proteins (inflammatory cytokines), known as a cytokine storm, that in and of itself leads to death. The object of this research is to screen, in a mouse influenza model, agents known to prevent this occurring and antagonise it once it has occurred. This will be done with and without Tamiflu, a standard anti-influenza drug.Read moreRead less
Using Clinical And Economic Evidence To Infrom Local Decision Making In Cancer Care
Funder
National Health and Medical Research Council
Funding Amount
$1,836,745.00
Summary
Medicines used to treat cancer often come with a high price tag. Many countries, including Australia, are no longer able to provide free access to all medicines. For this reason, patients and their families, public hospitals and private health insurers are often asked to pay for these treatments. Currently, health professionals and patients are ill-equipped to make informed treatment choices, since both cost and efficacy must be considered. Our proposed research will address this important gap i ....Medicines used to treat cancer often come with a high price tag. Many countries, including Australia, are no longer able to provide free access to all medicines. For this reason, patients and their families, public hospitals and private health insurers are often asked to pay for these treatments. Currently, health professionals and patients are ill-equipped to make informed treatment choices, since both cost and efficacy must be considered. Our proposed research will address this important gap in current knowledge. We will use a unique web-based resource (Cancer Institute NSW Standard Cancer Treatment Program; CI-SCaT) to communicate the economic evidence needed to make informed decisions about cancer treatments. Our project will provide public access to information about the effectiveness and costs of cancer drugs. This is a world first. CI-SCaT is already the main vehicle of communication about cancer drug treatments in NSW and is widely used by cancer health professionals and patients to inform point-of-care decisions. Our project we will also identify the factors which influence the ability of cancer treatment centres to make best use of their drug budgets. By achieving this goal, we hope to demonstrate how to best use scarce resources for the benefit of all cancer patients.Read moreRead less